Research programme: respiratory disorder therapeutics - PARI Pharma

Drug Profile

Research programme: respiratory disorder therapeutics - PARI Pharma

Alternative Names: Disodium Cromoglycate - PARI; DSCG - PARI Pharma; Levofloxacin VibrENT; Sodium cromoglicate - PARI Pharma

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PARI Pharma GmbH
  • Class Benzopyrans; Chromones; Fluoroquinolones; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; Mast cell stabilisers; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Rhinosinusitis

Highest Development Phases

  • No development reported Rhinosinusitis
  • Discontinued Asthma

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Rhinosinusitis in Germany (Inhalation)
  • 11 Sep 2013 Research programme: respiratory disorder therapeutics - PARI Pharma is available for licensing as of 11 Sep 2013.
  • 26 Jan 2010 Preclinical trials in Asthma in Germany (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top